Merck’s WELIREG Gains EU CHMP Backing for VHL Tumors and Advanced RCC
Merck known as MSD outside the United States and Canada, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending…
Lynparza Shows Survival Benefit in Early Breast Cancer: OlympiA Trial
Updated results from the OlympiA Phase III trial revealed that AstraZeneca and MSD’s Lynparza (olaparib) continues to show significant, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS),…
Pfizer’s IBRANCE Extends Progression-Free Survival in HR+, HER2+ Breast Cancer
Pfizer and Alliance Foundation Trials, LLC (AFT) recently unveiled findings from the Phase 3 PATINA trial, highlighting the potential of IBRANCE (palbociclib) in improving outcomes for patients with hormone receptor-positive…
Cyrus Biotechnology Announces Redosability of IdeS Protease for IgG-driven Autoimmune Disease
Cyrus Biotechnology, Inc. has announced new data demonstrating the potent activity of its engineered IgG-degrading enzyme, CYR241, in a rabbit redosing model. Importantly, the study revealed that CYR241 does not…
SonarMD Data Reveals Anxiety Increases Risks of IBD Flares and Severity
SonarMD, a leading platform for value-based care (VBC) focused on complex, chronic gastrointestinal conditions, has presented new clinical findings at the Advances in Inflammatory Bowel Diseases (AIBD) conference in Orlando,…
Antisense & RNAi Therapeutics Market 2024: Key Players Overview
The global market for Antisense & RNAi therapeutics is poised for significant growth, with projections estimating its value at US$5.4 billion in 2024. This market is expected to expand at…
Menarini and MEDSIR Present Phase III ADELA Study: New Strategy for Advanced Breast Cancer
Menarini Group, Stemline Therapeutics, and MEDSIR have presented groundbreaking research on the ADELA clinical trial, which targets therapeutic resistance in advanced ER+/HER2- breast cancer. This research was shared at the…
Sirius Therapeutics Reports Promising Phase I Data for Next-Gen Anticoagulant
Sirius Therapeutics has announced promising preliminary results from its Phase 1 first-in-human clinical trial of SRSD107, a next-generation siRNA therapeutic under development for the prevention and treatment of thromboembolic disorders.…
Health Canada Approves Celltrion’s Omlyclo (CT-P39), Canada’s First Omalizumab Biosimilar
Celltrion has announced that Health Canada has approved Omlyclo™, the first and only biosimilar referencing Xolair® (omalizumab) in Canada. Omlyclo™ is now authorized for the treatment of adults and adolescents…
SK Pharmteco Combines Leading Brands to Establish a Global CDMO Powerhouse
SK pharmteco, a global leader in contract development, manufacturing, and analytical testing services for the pharmaceutical and cell & gene therapy industries, has announced a groundbreaking brand unification initiative. This…
Crown Bioscience Receives 2024 Fierce CRO Award for Outstanding Client Service and Partnership
Crown Bioscience, a leading global contract research organization (CRO) based in the United States and a part of JSR Life Sciences and Japan’s JSR Corporation, has been awarded the prestigious…
City of Hope Experts Showcase Innovative Cancer Therapies at ASH Annual Conference
City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S., presented groundbreaking findings at the ASH Annual Conference in San Diego from…